Hepatitis C Lambda study

Participants will be randomized to 1 of 2 study medication groups: Lambda + ribavirin + daclatasvir (Group 1) or alfa + ribavirin + telaprevir (Group 2). There will be twice as many participants assigned to Group 1. Both the lambda and the alfa medications are self-injected under the skin once a week; all other medications are taken by mouth. Blood samples will be taken periodically to test immune system response. Duration of the study is expected to be 48 to 72 weeks, including post-treatment follow-up. There is also an optional pharmacogenetic (study of genes) sub-study where, if participants agree, they will provide an additional blood sample and health information. Participants can take part in the main study without taking part in the pharmacogenetic sub-study.